Goldman Sachs downgraded partly on ‘disappointing’ start to 2025 dealmaking
Expectations of a banner year in dealmaking have not yet materialized due to worries about inflation and uncertainties over U ...
Fintel on MSN12h
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation
Fintel reports that on February 28, 2025, Goldman Sachs initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy ...
Goldman Sachs Pours Cold Water on Palantir Technologies’ (PLTR) Stock Flame
Palantir Technologies (PLTR) has been among the best-performing stocks over the past 12 months, driven by improving earnings, ...
Hosted on MSN1h
DigitalOcean price target raised to $46 from $44 at Goldman Sachs
Goldman Sachs raised the firm’s price target on DigitalOcean (DOCN) to $46 from $44 and keeps a Buy rating on the shares. The company reported a ...
Goldman Says ‘Headline Roulette’ Prevents Buy-the-Dip in Stocks
Dip buyers are missing in action as the narrative for stocks is quickly souring due to the negative news flow on trade.
General Motors price target raised to $73 from $72 at Goldman Sachs
Goldman Sachs raised the firm’s price target on General Motors (GM) to $73 from $72 and keeps a Buy rating on the shares. The firm cites the ...
Hosted on MSN1h
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating on ...